Page Title
Clinical Trial Finder
You can help advance cystic fibrosis research — starting now.
Tailor your search using the filters on the left.
Need help? Watch a video tutorial or contact the Clinical Trial Navigator, a real person who can assist you.
Showing 1-2 of 2 studies
Tailor your search using the filters on the left.
Need help? Watch a video tutorial or contact the Clinical Trial Navigator, a real person who can assist you.
Showing 1-2 of 2 studies
-
Anti-InfectiveCompleted with Results
Arikace for Nontuberculous Mycobacteria (NTM) , protocol number Insmed 112This study looked at the safety and effectiveness of liposomal amikacin for inhalation (Arikace™), in treating nontuberculous mycobacterial lung disease (NTM).
-
Age:
12 Years to 75 Years
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
0
-
Length of Participation:
12 weeks
-
-
Anti-InfectiveCompleted with Results
Amikacin for Inhalation (Transave) , protocol number Insmed TR02-106This study evaluated the safety and efficacy of a new inhaled antibiotic, Liposomal Amikacin (Arikace) to treat people with CF and chronic Pseudomonas aeruginosa lung infection.
-
Age:
6 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
11
-
Length of Participation:
56 days
-
Showing 1-2 of 2 studies
- 1
Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.
Related Topics
CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More